Our top pick for
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Alexion Pharmaceuticals Inc is a biotechnology business based in the US. Alexion Pharmaceuticals shares (ALXN) are listed on the NASDAQ and all prices are listed in US Dollars. Alexion Pharmaceuticals employs 3,837 staff and has a trailing 12-month revenue of around $6.3 billion.
|Latest market close||$177.12|
|52-week range||$0.00 - $0.00|
|50-day moving average||$182.75|
|200-day moving average||$165.77|
|Wall St. target price||$177.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$3.08|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-19)||N/A|
|1 month (2022-08-26)||N/A|
|3 months (2022-06-26)||N/A|
|6 months (2022-03-26)||N/A|
|1 year (2021-09-26)||N/A|
|2 years (2020-09-30)||54.78%|
|3 years (2019-09-30)||80.85%|
|5 years (2017-09-29)||26.25%|
Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Alexion Pharmaceuticals shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1706. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.
The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$6.3 billion|
|Operating margin TTM||47.41%|
|Gross profit TTM||$5.5 billion|
|Return on assets TTM||10.08%|
|Return on equity TTM||4.43%|
|Market capitalisation||$40.3 billion|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.21
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 28.21 (as at 01/01/2019) is pretty good – landing it in it in the 26th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 8.12/100
Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.78/100
Alexion Pharmaceuticals's social score of 17.78 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 15.31/100
Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.
|Total ESG score||28.21|
|Total ESG percentile||26.48|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
|Level of controversy||2|
We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.
Alexion Pharmaceuticals's shares were split on a 2:1 basis on 23 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.
Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.2595. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.